Narjust Florez, MD

Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss key adverse effects to watch and management strategies in EGFR-mutated NSCLC.

Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss how nurse practitioners add valuable insight to treatment selection in EGFR-mutated NSCLC.

Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss communication strategies between specialists and patients in EGFR-mutated NSCLC management.

Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss initial conversations and methods of support for patients with EGFR-mutated NSCLC.

Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss how care providers help drive treatment adherence in EGFR-mutated NSCLC.

High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for quicker symptom relief.

High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for rapid symptom relief.

New subcutaneous amivantamab cuts infusion reactions and steroid burden, reduces clinic visits, and shows improved outcomes in PALOMA-3.

PALOMA-3: subcutaneous amivantamab matches IV levels, slashes infusion reactions and steroids, and shortens clinic time.

New data show subcutaneous amivantamab matches IV efficacy, cuts infusion reactions and steroid prep, and slashes clinic time and costs.

Compare first-line EGFR-mutated lung cancer options: amivantamab combos vs osimertinib plus chemo, weighing survival, MET amplification coverage, toxicity, and visits.

Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Narjust Florez, MD, discusses the publication of a consensus manuscript in Cancer on recommendations for clinical strategies for lung cancer management.

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Narjust Florez, MD, discusses treatment preferences in borderline resectable NSCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.